A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma
BackgroundClear cell renal cell carcinoma (ccRCC) is a malignant disease containing tumor-infiltrating lymphocytes. Reactive oxygen species (ROS) are present in the tumor microenvironment and are strongly associated with cancer development. Nevertheless, the role of ROS-related genes in ccRCC remain...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1202151/full |
| _version_ | 1797783067011579904 |
|---|---|
| author | Hongxiang Liu Hongxiang Liu Yong Luo Shankun Zhao Jing Tan Minjian Chen Xihai Liu Jianheng Ye Shanghua Cai Shanghua Cai Yulin Deng Jinchuang Li Huichan He Xin Zhang Weide Zhong Weide Zhong Weide Zhong Weide Zhong Weide Zhong |
| author_facet | Hongxiang Liu Hongxiang Liu Yong Luo Shankun Zhao Jing Tan Minjian Chen Xihai Liu Jianheng Ye Shanghua Cai Shanghua Cai Yulin Deng Jinchuang Li Huichan He Xin Zhang Weide Zhong Weide Zhong Weide Zhong Weide Zhong Weide Zhong |
| author_sort | Hongxiang Liu |
| collection | DOAJ |
| description | BackgroundClear cell renal cell carcinoma (ccRCC) is a malignant disease containing tumor-infiltrating lymphocytes. Reactive oxygen species (ROS) are present in the tumor microenvironment and are strongly associated with cancer development. Nevertheless, the role of ROS-related genes in ccRCC remains unclear.MethodsWe describe the expression patterns of ROS-related genes in ccRCC from The Cancer Genome Atlas and their alterations in genetics and transcription. An ROS-related gene signature was constructed and verified in three datasets and immunohistochemical staining (IHC) analysis. The immune characteristics of the two risk groups divided by the signature were clarified. The sensitivity to immunotherapy and targeted therapy was investigated.ResultsOur signature was constructed on the basis of glutamate-cysteine ligase modifier subunit (GCLM), interaction protein for cytohesin exchange factors 1 (ICEF1), methionine sulfoxide reductase A (MsrA), and strawberry notch homolog 2 (SBNO2) genes. More importantly, protein expression levels of GCLM, MsrA, and SBNO2 were detected by IHC in our own ccRCC samples. The high-risk group of patients with ccRCC suffered lower overall survival rates. As an independent predictor of prognosis, our signature exhibited a strong association with clinicopathological features. An accurate nomogram for improving the clinical applicability of our signature was constructed. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses showed that the signature was closely related to immune response, immune activation, and immune pathways. The comprehensive results revealed that the high-risk group was associated with high infiltration of regulatory T cells and CD8+ T cells and more benefited from targeted therapy. In addition, immunotherapy had better therapeutic effects in the high-risk group.ConclusionOur signature paved the way for assessing prognosis and developing more effective strategies of immunotherapy and targeted therapy in ccRCC. |
| first_indexed | 2024-03-13T00:19:52Z |
| format | Article |
| id | doaj.art-f45e4641bc9146c2a6ca7a4ee9a0077b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-13T00:19:52Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f45e4641bc9146c2a6ca7a4ee9a0077b2023-07-11T16:42:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-07-011310.3389/fonc.2023.12021511202151A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinomaHongxiang Liu0Hongxiang Liu1Yong Luo2Shankun Zhao3Jing Tan4Minjian Chen5Xihai Liu6Jianheng Ye7Shanghua Cai8Shanghua Cai9Yulin Deng10Jinchuang Li11Huichan He12Xin Zhang13Weide Zhong14Weide Zhong15Weide Zhong16Weide Zhong17Weide Zhong18School of Medicine, Jinan University, Guangzhou, ChinaDepartment of Urology, The First People’s Hospital of Zhaoqing, Zhaoqing, ChinaDepartment of Urology, The Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, ChinaDepartment of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, ChinaDepartment of Pediatrics, The First People’s Hospital of Zhaoqing, Zhaoqing, ChinaDepartment of Urology, The First People’s Hospital of Zhaoqing, Zhaoqing, ChinaDepartment of Urology, The First People’s Hospital of Zhaoqing, Zhaoqing, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaGuangzhou Medical University, Guangzhou Laboratory, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, ChinaGuangzhou Medical University, Guangzhou Laboratory, Guangzhou, ChinaDepartment of Pathology, The Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, ChinaSchool of Medicine, Jinan University, Guangzhou, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaGuangzhou Medical University, Guangzhou Laboratory, Guangzhou, China0Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, Macao SAR, ChinaBackgroundClear cell renal cell carcinoma (ccRCC) is a malignant disease containing tumor-infiltrating lymphocytes. Reactive oxygen species (ROS) are present in the tumor microenvironment and are strongly associated with cancer development. Nevertheless, the role of ROS-related genes in ccRCC remains unclear.MethodsWe describe the expression patterns of ROS-related genes in ccRCC from The Cancer Genome Atlas and their alterations in genetics and transcription. An ROS-related gene signature was constructed and verified in three datasets and immunohistochemical staining (IHC) analysis. The immune characteristics of the two risk groups divided by the signature were clarified. The sensitivity to immunotherapy and targeted therapy was investigated.ResultsOur signature was constructed on the basis of glutamate-cysteine ligase modifier subunit (GCLM), interaction protein for cytohesin exchange factors 1 (ICEF1), methionine sulfoxide reductase A (MsrA), and strawberry notch homolog 2 (SBNO2) genes. More importantly, protein expression levels of GCLM, MsrA, and SBNO2 were detected by IHC in our own ccRCC samples. The high-risk group of patients with ccRCC suffered lower overall survival rates. As an independent predictor of prognosis, our signature exhibited a strong association with clinicopathological features. An accurate nomogram for improving the clinical applicability of our signature was constructed. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses showed that the signature was closely related to immune response, immune activation, and immune pathways. The comprehensive results revealed that the high-risk group was associated with high infiltration of regulatory T cells and CD8+ T cells and more benefited from targeted therapy. In addition, immunotherapy had better therapeutic effects in the high-risk group.ConclusionOur signature paved the way for assessing prognosis and developing more effective strategies of immunotherapy and targeted therapy in ccRCC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1202151/fullclear cell renal cell carcinomareactive oxygen speciesprognosisimmune infiltratesimmunotherapy |
| spellingShingle | Hongxiang Liu Hongxiang Liu Yong Luo Shankun Zhao Jing Tan Minjian Chen Xihai Liu Jianheng Ye Shanghua Cai Shanghua Cai Yulin Deng Jinchuang Li Huichan He Xin Zhang Weide Zhong Weide Zhong Weide Zhong Weide Zhong Weide Zhong A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma Frontiers in Oncology clear cell renal cell carcinoma reactive oxygen species prognosis immune infiltrates immunotherapy |
| title | A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma |
| title_full | A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma |
| title_fullStr | A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma |
| title_full_unstemmed | A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma |
| title_short | A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma |
| title_sort | reactive oxygen species related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma |
| topic | clear cell renal cell carcinoma reactive oxygen species prognosis immune infiltrates immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1202151/full |
| work_keys_str_mv | AT hongxiangliu areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT hongxiangliu areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT yongluo areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT shankunzhao areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT jingtan areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT minjianchen areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT xihailiu areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT jianhengye areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT shanghuacai areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT shanghuacai areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT yulindeng areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT jinchuangli areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT huichanhe areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT xinzhang areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong areactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT hongxiangliu reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT hongxiangliu reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT yongluo reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT shankunzhao reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT jingtan reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT minjianchen reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT xihailiu reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT jianhengye reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT shanghuacai reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT shanghuacai reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT yulindeng reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT jinchuangli reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT huichanhe reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT xinzhang reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma AT weidezhong reactiveoxygenspeciesrelatedsignaturetopredictprognosisandaidimmunotherapyinclearcellrenalcellcarcinoma |